- Previous Close
3.5300 - Open
3.6000 - Bid 3.4800 x --
- Ask 3.5100 x --
- Day's Range
3.4700 - 3.6000 - 52 Week Range
3.2900 - 4.9000 - Volume
10,137 - Avg. Volume
16,656 - Market Cap (intraday)
100.622M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4700 - Earnings Date Mar 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.60
Aiforia Technologies Oyj, together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software for translating images into discoveries, decisions, and diagnoses in Finland, rest of Europe, North America, and internationally. The company offers AI-supported image-based diagnostic suites for breast cancer, lung cancer, and prostate cancer. It also provides Aiforia Create, which allows users to create and validate their own proprietary deep learning AI models, as well as train their AI models to identify, quantify, or measure features in any 2D image; and Aiforia Studies, a software module that offers AI-assisted image analysis workflow within the framework of good laboratory practices. In addition, the company offers integration, cloud hosting, and custom AI services. It serves pharmaceutical and biotechnology companies, contract research organizations, clinical laboratories, academic institutions, and other industries. Aiforia Technologies Oyj was incorporated in 2013 and is headquartered in Helsinki, Finland.
www.aiforia.com78
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AIFORIA.HE
View MorePerformance Overview: AIFORIA.HE
Trailing total returns as of 1/22/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AIFORIA.HE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AIFORIA.HE
View MoreValuation Measures
Market Cap
100.62M
Enterprise Value
89.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
32.72
Price/Book (mrq)
4.61
Enterprise Value/Revenue
31.87
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.29%
Return on Equity (ttm)
-54.79%
Revenue (ttm)
2.81M
Net Income Avi to Common (ttm)
-12.36M
Diluted EPS (ttm)
-0.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
17.92M
Total Debt/Equity (mrq)
31.29%
Levered Free Cash Flow (ttm)
-8.39M